| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/04/2009 | CN101357947A Preparation and application of tumour vascular targeting agent VEGF*/RIP30fusion toxin |
| 02/04/2009 | CN101357946A Cholesterol metabolic regulation protein and use thereof |
| 02/04/2009 | CN101357230A Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 02/04/2009 | CN101357227A Senile dementia recombinant adenovirus gene vaccine and preparation method thereof |
| 02/04/2009 | CN101357225A Preparation method of medicine for treating elderly cerebral dysfunction |
| 02/04/2009 | CN101357224A Kidney-tonifying and health-preserving preparation |
| 02/04/2009 | CN101357223A Preparation method of anti-stress agent for fishing |
| 02/04/2009 | CN100457916C Solid fermenting method for vitacoenzyme medicine |
| 02/04/2009 | CN100457908C Recombinant stratum corneum chymotryptic enzyme (SCCE) |
| 02/04/2009 | CN100457897C Preparation process of and use of thrombus dissolving enzyme |
| 02/04/2009 | CN100457781C Antibodies against cancer |
| 02/04/2009 | CN100457778C Mutant of ciliary nerves trophic factor (CNTF), producing method and usage |
| 02/04/2009 | CN100457777C Leucine-based motif and clostridial neurotoxins |
| 02/04/2009 | CN100457775C Polypeptides having brain disposition activity and utilization of the same |
| 02/04/2009 | CN100457189C Fusions of cytokines and tumor targeting proteins |
| 02/04/2009 | CN100457187C VEGF slowly releasing injection microsphere support and its preparation and use |
| 02/04/2009 | CN100457184C Multi-stage oral drug controlled-release system |
| 02/04/2009 | CN100457178C Process for preparing bone peptide injection |
| 02/04/2009 | CN100457118C 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
| 02/04/2009 | CN100457094C Preparing process of biodegradable capsule loading medicine and nano magnetic particle |
| 02/04/2009 | CN100456950C Use of iodine for preparing diet preventing hyperthyroidism of cat |
| 02/04/2009 | CN100456946C Oilseed processing |
| 02/03/2009 | US7485713 Polypeptides comprising growth hormone receptor extracellular domain and glycosylphosphatidylinositol |
| 02/03/2009 | US7485712 A DNA sequence encoding a novel neuronal protein kinase (NPK) which phosphorylates tau proteins; for the treatment of Alzheimer's disease and cancer, diagnostic kits and in vitro diagnostic methods for the diseases |
| 02/03/2009 | US7485709 Identification of a novel BHD gene |
| 02/03/2009 | US7485708 Nucleic acids encoding ara h 3 polypeptides |
| 02/03/2009 | US7485702 Homogeneous preparations of IL-28A cysteine mutants |
| 02/03/2009 | US7485701 Homogeneous preparations of IL-28 and IL-29 |
| 02/03/2009 | US7485700 Interferon-like protein ZCYTO21 |
| 02/03/2009 | US7485698 Administering a polypeptide as an antitumor or anticarcinogenic agent; (giant cell) glioblastoma, gliosarcoma; anaplastic astrocytoma, oligodendroglioma, ganglioglioma or ependymoma; medulloepithelioma, ependymoblastoma, medulloblastoma, and other brain cancers; side effect reduction |
| 02/03/2009 | US7485697 Nucleotide sequences coding receptor for advanced glycation endproducts (RAGE) for identifying modulators for treatment and prevention of cell proliferative and cardiovascular disorders |
| 02/03/2009 | US7485628 Inhibition of STAT-1 |
| 02/03/2009 | US7485626 Biosynthesis of Dna ; cell proliferation; overlapping enzyme activation ; mixture of proteolytic enzyme and dipeptidyl peptidase inhibitors; autoimmune disease; antiinflammatory agents graft versus host diease |
| 02/03/2009 | US7485625 Inhibitors of hepatitis C virus NS3/NS4a serine protease |
| 02/03/2009 | US7485624 administering a neurotoxin, specifically a botulinum toxin, to treat disorders such as cardiac arrhythmias |
| 02/03/2009 | US7485622 Paralytic peptide for use in neuromuscular therapy |
| 02/03/2009 | US7485621 Tumor tag and the use thereof |
| 02/03/2009 | US7485620 Use in the control of glycemia in aging patients, GH deficient patients, diabetic patients and obese patients |
| 02/03/2009 | US7485618 FGF-5 supported and binding peptides |
| 02/03/2009 | US7485617 Osteoinductive materials |
| 02/03/2009 | US7485616 Methods of investigating, diagnosing, and treating amyloidosis |
| 02/03/2009 | US7485468 Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
| 02/03/2009 | US7485459 Human neuronal attachment factor-1 antibodies |
| 02/03/2009 | US7485456 Drug screening for a molecule capable of binding to NIK (nuclear factor kappa B inducing kinase); DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, isoforms, analogs, fragments and derivatives; gene expression |
| 02/03/2009 | US7485439 Nucleic acids encoding plasminogen fragments and methods of use |
| 02/03/2009 | US7485438 Method of producing polyvalent antigens |
| 02/03/2009 | US7485429 Genetically engineered polypeptide comprising extracellular domain of integrin subunit alpha 11; marker or target of all types of cells; drugs, vaccines |
| 02/03/2009 | US7485427 High affinity for streptavidin/avidin; biotinyl moiety linked to a photoreactive group covalently bound to substrate (proteins, peptides, amino acids, and nucleic acids); Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered |
| 02/03/2009 | US7485422 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers |
| 02/03/2009 | US7485323 Blend of 90-95% of a proteolytic hydrolized gelatin having an average primary amine content of 1.0x10-3 to 1.0x10-2 mu mol of primary amine per mu g of hydrolysate and 5-10% of gelatin; average viscosity of 10 to 15 cP; improved crosslinking and dissolution properties. |
| 02/03/2009 | US7485321 Synthetic polypeptide ligand having a 12-mer L-peptide for targeting pharmaceutical agents to intestinal epithelial tissue; when integrated as an N-terminal PIII fusion peptide of an M13 phage it can bind the phage to Caco-2 cell, IEC-6 cell, rat, mouse, pig or dog homogenate membrane fractions |
| 02/03/2009 | US7485314 Induction of antigen specific immunologic tolerance |
| 02/03/2009 | US7485313 Administering an isolated and purified recombinant Chlamydia trachomatis pgp3 protein having its native amino acid conformation to elicit an immune response to a recombinant Chlamydia trachomatis pgp3 protein |
| 02/03/2009 | US7485311 Vascular endothelial growth factor, brain derived neurotrophic factor and/or basic fibroblast growth factor |
| 02/03/2009 | US7485310 Use of CXCL6 chemokine in the prevention or repair of cartilage defects |
| 02/03/2009 | US7485308 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor |
| 02/03/2009 | US7485306 Lutzomyia longipalpis polypeptides and methods of use |
| 02/03/2009 | US7485304 Non-toxic mucosal adjuvant |
| 02/03/2009 | US7485299 Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 02/03/2009 | US7485298 Diagnosis and treatment of human dormancy-related sequellae |
| 02/03/2009 | US7485296 Using monoclonal antibodies specific for prostate stem cell antigen (PSCA) for use in diagnosis and treatment of cell proliferfative disorders; immunodiagnostics; immunotherapy |
| 02/03/2009 | US7485295 Compositions and methods of using chondroitinase ABCI mutants |
| 02/03/2009 | US7485294 Galenic pectinate formulation for colon-targeted delivery of antibiotic-inactivating enzymes and method of use thereof |
| 02/03/2009 | CA2446615C Nutritional composition for the treatment of connective tissue |
| 02/03/2009 | CA2341397C Immediate release tablet |
| 02/03/2009 | CA2286165C A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin |
| 02/03/2009 | CA2185565C Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases |
| 02/03/2009 | CA2152066C Protein conferring an inducible resistance to glycopeptides, particularly in gram-positive bacteria |
| 02/03/2009 | CA2150925C Improved synthesis of polymer bio-active conjugates |
| 02/03/2009 | CA2128504C High concentration homogenized collagen compositions |
| 02/03/2009 | CA1341590C Human immune interferon |
| 01/29/2009 | WO2009015385A1 Antimicrobial peptide, compositions , and methods of use |
| 01/29/2009 | WO2009015384A1 Nucleic acid binding compounds and methods of use |
| 01/29/2009 | WO2009015382A2 Novel peptides that enhance tight junction permeability |
| 01/29/2009 | WO2009015372A1 Photo-protective dermatological formulations and methods of using the same |
| 01/29/2009 | WO2009015345A1 Pharmaceutical compositions comprising fc fusion proteins |
| 01/29/2009 | WO2009015336A2 Controlled release interferon drug products and treatment of hcv infection using same |
| 01/29/2009 | WO2009015314A2 Modified lecithin-cholesterol acyltransferase enzymes |
| 01/29/2009 | WO2009015283A2 Bhc80 - histone complexes and uses thereof |
| 01/29/2009 | WO2009015087A2 Compositions and methods for treatment of trauma |
| 01/29/2009 | WO2009015011A1 Natriuretic polypeptides |
| 01/29/2009 | WO2009014919A2 H2n3 influenza a viruses and methods of use |
| 01/29/2009 | WO2009014745A1 Antibodies to cd200 and uses thereof in inhibiting immune responses |
| 01/29/2009 | WO2009014702A2 Cd74 for use in the treatment of cancer and liver toxicity |
| 01/29/2009 | WO2009014633A1 Method of treating acute respiratory distress syndrome |
| 01/29/2009 | WO2009014624A2 Nrf2 inducers for treating epidermolysis bullosa simplex |
| 01/29/2009 | WO2009014564A2 Modified plasminogen activator inhibitor type-1 molecule and methods based thereon |
| 01/29/2009 | WO2009014450A1 Novel peptides with anti-tumor activity |
| 01/29/2009 | WO2009014440A1 Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides |
| 01/29/2009 | WO2009014382A2 Cxcl11 adjuvant compositions and uses thereof |
| 01/29/2009 | WO2009013794A1 INSULIN SECRETION INDUCER, AND ACCELERATOR OF INCREASE IN PANCREATIC β-CELLS |
| 01/29/2009 | WO2009013753A1 Peptides derived from plasminogen activator inhibitor-1 and uses thereof |
| 01/29/2009 | WO2009013622A2 Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof |
| 01/29/2009 | WO2009013559A1 Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof |
| 01/29/2009 | WO2009013543A2 Targeted binging agents directed to kdr and uses thereof - 035 |
| 01/29/2009 | WO2009013484A1 Immune modulation via c-type lectin |
| 01/29/2009 | WO2009013251A1 Use of mutated antithrombins for treating or preventing coagulation disorders |
| 01/29/2009 | WO2009013024A1 Medical device and use of a pharmaceutical composition |
| 01/29/2009 | WO2009012986A1 Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| 01/29/2009 | WO2009012958A2 Tubulysin d analogues |